The gastrointestinal therapeutics market for Irritable Bowel Syndrome , Ulcerative Colitis and Crohn's Disease in the Asia-Pacific region will increase in value from $564m in 2012 to $784m by 2019, at a Compound Annual Growth Rate of 4.8%, according to a new report from business intelligence provider GBI Research.
More...
More...